Procept Biorobotics Corp Financials
Procept Biorobotics Corp (PRCT) reported $308.1M in revenue for fiscal year 2025, up 37.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Scale is improving unit economics, but commercial spending still outruns gross profit, keeping this fast-growing business cash-consuming.
Between FY2024 and FY2025, operating cash burn improved from-$99.2M to-$49.0M . That happened even though operating loss remained about-$100M and capex climbed to$9.4M , a sign that cash conversion is improving as scale rises.
The core product is becoming structurally more attractive: gross margin expanded from
The balance sheet still reflects a business funded mainly by earlier equity raises rather than rising leverage: cash ended FY2025 at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Procept Biorobotics Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Procept Biorobotics Corp has an operating margin of -33.7%, meaning the company loses $34 on every $100 of revenue. This results in a profitability score of 23/100. This is up from -43.0% the prior year.
Procept Biorobotics Corp's revenue surged 37.2% year-over-year to $308.1M, reflecting rapid business expansion. This strong growth earns a score of 94/100.
Procept Biorobotics Corp carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.85, Procept Biorobotics Corp holds $6.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
Procept Biorobotics Corp's operations used $49.0M of cash, and capex of $9.4M added to the outflow, for a free cash flow shortfall of $58.3M. This results in a cash flow score of 9/100.
Procept Biorobotics Corp's ROE of 0.0% shows moderate profitability relative to equity, earning a score of 34/100. This is unchanged from the prior year.
Procept Biorobotics Corp scores 4.31, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($142.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Procept Biorobotics Corp passes 2 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Procept Biorobotics Corp reported a net loss of $96K while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Procept Biorobotics Corp reported an operating loss of $103.9M against $3.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Procept Biorobotics Corp generated $308.1M in revenue in fiscal year 2025. This represents an increase of 37.2% from the prior year.
Procept Biorobotics Corp's EBITDA was -$97.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.7% from the prior year.
Procept Biorobotics Corp reported -$96K in net income in fiscal year 2025. This represents a decrease of 4.5% from the prior year.
Procept Biorobotics Corp earned -$1.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1.7% from the prior year.
Cash & Balance Sheet
Procept Biorobotics Corp recorded an outflow of $58.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 43.7% from the prior year.
Procept Biorobotics Corp held $286.5M in cash against $51.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Procept Biorobotics Corp's gross margin was 63.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.6 percentage points from the prior year.
Procept Biorobotics Corp's operating margin was -33.7% in fiscal year 2025, reflecting core business profitability. This is up 9.3 percentage points from the prior year.
Procept Biorobotics Corp's net profit margin was 0.0% in fiscal year 2025, showing the share of revenue converted to profit. That is unchanged from the prior year.
Procept Biorobotics Corp's ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. That is unchanged from the prior year.
Capital Allocation
Procept Biorobotics Corp invested $71.3M in research and development in fiscal year 2025. This represents an increase of 14.4% from the prior year.
Procept Biorobotics Corp invested $9.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 112.2% from the prior year.
Not reported for fiscal year 2025.
PRCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $337.3M | $308.1M+37.2% | $224.5M+64.8% | $136.2M+81.6% | $75.0M+117.6% | $34.5M+346.7% | $7.7M |
| Cost of Revenue | $120.7M | $111.8M+28.0% | $87.4M+34.2% | $65.1M+71.7% | $37.9M+103.8% | $18.6M+107.4% | $9.0M |
| Gross Profit | $216.6M | $196.2M+43.1% | $137.1M+93.0% | $71.0M+91.6% | $37.1M+133.8% | $15.9M+1364.1% | -$1.3M |
| R&D Expenses | $78.8M | $71.3M+14.4% | $62.3M+28.6% | $48.4M+67.2% | $29.0M+52.6% | $19.0M+16.7% | $16.3M |
| SG&A Expenses | $252.1M | $228.8M+33.5% | $171.4M+30.1% | $131.8M+48.3% | $88.8M+74.0% | $51.0M+68.6% | $30.3M |
| Operating Income | -$114.2M | -$103.9M-7.5% | -$96.6M+11.5% | -$109.2M-35.2% | -$80.7M-49.0% | -$54.2M-13.3% | -$47.8M |
| Interest Expense | $3.5M | $3.6M-14.3% | $4.2M+4.7% | $4.0M-22.9% | $5.2M-10.8% | $5.8M+10.4% | $5.3M |
| Income Tax | N/A | $190K-48.4% | $368K+360.0% | $80K | $0 | $0 | $0 |
| Net Income | -$14.3M | -$96K-4.5% | -$91K+13.7% | -$106K-21.5% | -$87K-45.6% | -$60K+99.9% | -$53.0M |
| EPS (Diluted) | — | -$1.72+1.7% | -$1.75+21.9% | -$2.24-14.3% | -$1.96 | -$3.63 | -$14.47 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PRCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $508.1M-4.9% | $534.0M+31.9% | $404.7M+30.8% | $309.3M-8.2% | $337.0M+167.5% | $126.0M |
| Current Assets | $450.4M-6.5% | $481.8M+37.4% | $350.6M+28.6% | $272.6M-16.4% | $326.2M+195.8% | $110.3M |
| Cash & Equivalents | $286.5M-14.1% | $333.7M+29.7% | $257.2M+15.9% | $221.9M-27.1% | $304.3M+203.9% | $100.1M |
| Inventory | $70.7M+25.9% | $56.2M+41.3% | $39.8M+39.3% | $28.5M+117.1% | $13.1M+89.9% | $6.9M |
| Accounts Receivable | $83.5M0.0% | $83.5M+72.6% | $48.4M+216.8% | $15.3M+242.1% | $4.5M+188.2% | $1.5M |
| Total Liabilities | $142.2M+7.9% | $131.8M+6.3% | $124.0M+10.4% | $112.3M+60.5% | $69.9M-77.4% | $308.9M |
| Current Liabilities | $65.8M+23.8% | $53.1M+15.7% | $45.9M+30.1% | $35.3M+117.3% | $16.2M+11.8% | $14.5M |
| Long-Term Debt | $51.6M+0.3% | $51.5M+0.3% | $51.3M+0.2% | $51.2M+2.4% | $50.0M+12.6% | $44.4M |
| Total Equity | $365.9M-9.0% | $402.2M+43.3% | $280.8M+42.5% | $197.1M-26.2% | $267.1M+246.0% | -$182.9M |
| Retained Earnings | -$641.6M-17.5% | -$546.0M-20.1% | -$454.6M-30.4% | -$348.7M-33.3% | -$261.5M-29.7% | -$201.7M |
Not reported in any period shown, so not listed: Goodwill.
PRCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$74.3M | -$49.0M+50.6% | -$99.2M+8.1% | -$108.0M-34.4% | -$80.4M-40.2% | -$57.3M-18.6% | -$48.3M |
| Capital Expenditures | $10.6M | $9.4M+112.2% | $4.4M-82.5% | $25.2M+850.1% | $2.7M+348.1% | $592K+154.1% | $233K |
| Free Cash Flow | -$84.9M | -$58.3M+43.7% | -$103.6M+22.2% | -$133.2M-60.4% | -$83.0M-43.3% | -$57.9M-19.2% | -$48.6M |
| Investing Cash Flow | -$10.6M | -$9.4M-112.2% | -$4.4M+82.5% | -$25.2M-850.1% | -$2.7M-348.1% | -$592K-154.1% | -$233K |
| Financing Cash Flow | $10.2M | $11.2M-93.8% | $180.1M+7.3% | $167.8M+4545.5% | $3.6M-98.6% | $262.1M+145.5% | $106.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PRCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Gross Margin | 63.7%+2.6pp | 61.1%+8.9pp | 52.2%+2.7pp | 49.4%+3.4pp | 46.0%+62.3pp | -16.3% |
| Operating Margin | -33.7%+9.3pp | -43.0%+37.1pp | -80.2% | -107.6% | -157.1% | -619.4% |
| Net Margin | 0.0%0.0pp | 0.0%0.0pp | -0.1%0.0pp | -0.1%+0.1pp | -0.2% | -687.0% |
| Return on Equity | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0% | N/A |
| Return on Assets | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%+42.1pp | -42.1% |
| Current Ratio | 6.85-2.2x | 9.07+1.4x | 7.63-0.1x | 7.73-12.4x | 20.08+12.5x | 7.59 |
| Debt-to-Equity | 0.140.0x | 0.13-0.1x | 0.18-0.1x | 0.26+0.1x | 0.19 | N/A |
| FCF Margin | -18.9%+27.2pp | -46.2%+51.6pp | -97.8% | -110.7% | -168.0% | -629.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Procept Biorobotics Corp Ranks
Frequently Asked Questions
What is Procept Biorobotics Corp's annual revenue?
Procept Biorobotics Corp (PRCT) reported $308.1M in total revenue for fiscal year 2025. This represents a 37.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Procept Biorobotics Corp's revenue growing?
Procept Biorobotics Corp (PRCT) revenue grew by 37.2% year-over-year, from $224.5M to $308.1M in fiscal year 2025.
Is Procept Biorobotics Corp profitable?
No, Procept Biorobotics Corp (PRCT) reported a net income of -$96K in fiscal year 2025, with a net profit margin of 0.0%.
What is Procept Biorobotics Corp's EBITDA?
Procept Biorobotics Corp (PRCT) had EBITDA of -$97.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Procept Biorobotics Corp have?
As of fiscal year 2025, Procept Biorobotics Corp (PRCT) had $286.5M in cash and equivalents against $51.6M in long-term debt.
What is Procept Biorobotics Corp's gross margin?
Procept Biorobotics Corp (PRCT) had a gross margin of 63.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Procept Biorobotics Corp's operating margin?
Procept Biorobotics Corp (PRCT) had an operating margin of -33.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Procept Biorobotics Corp's net profit margin?
Procept Biorobotics Corp (PRCT) had a net profit margin of 0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Procept Biorobotics Corp's return on equity (ROE)?
Procept Biorobotics Corp (PRCT) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Procept Biorobotics Corp's free cash flow?
Procept Biorobotics Corp (PRCT) recorded an outflow of $58.3M in free cash flow during fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Procept Biorobotics Corp's operating cash flow?
Procept Biorobotics Corp (PRCT) recorded an outflow of $49.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Procept Biorobotics Corp's total assets?
Procept Biorobotics Corp (PRCT) had $508.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Procept Biorobotics Corp's capital expenditures?
Procept Biorobotics Corp (PRCT) invested $9.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Procept Biorobotics Corp spend on research and development?
Procept Biorobotics Corp (PRCT) invested $71.3M in research and development during fiscal year 2025.
What is Procept Biorobotics Corp's current ratio?
Procept Biorobotics Corp (PRCT) had a current ratio of 6.85 as of fiscal year 2025, which is generally considered healthy.
What is Procept Biorobotics Corp's debt-to-equity ratio?
Procept Biorobotics Corp (PRCT) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Procept Biorobotics Corp's return on assets (ROA)?
Procept Biorobotics Corp (PRCT) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Procept Biorobotics Corp's cash runway?
Based on fiscal year 2025 data, Procept Biorobotics Corp (PRCT) had $286.5M in cash against an annual operating cash burn of $49.0M. This gives an estimated cash runway of approximately 70 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Procept Biorobotics Corp's Altman Z-Score?
Procept Biorobotics Corp (PRCT) has an Altman Z-Score of 4.31, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Procept Biorobotics Corp's Piotroski F-Score?
Procept Biorobotics Corp (PRCT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Procept Biorobotics Corp's earnings high quality?
Procept Biorobotics Corp (PRCT) reported a net loss of $96K while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Procept Biorobotics Corp cover its interest payments?
Procept Biorobotics Corp (PRCT) reported an operating loss of $103.9M against $3.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Procept Biorobotics Corp?
Procept Biorobotics Corp (PRCT) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.